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Abstract  Colorectal  cancer  (CRC)  is  one  of  the  most  important  causes  of  death  in  the  world.
Hereditary  CRC  is  found  in  5--10%  of  CRC  patients.  In  this  review,  we  will  focus  on  the  major  forms
of hereditary  CRC  and  their  management  according  to  the  most  recent  literature  available.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Avaliac¸ão  de  Doentes  com  Síndromas  Hereditários  Associados  ao  Cancro  Coloretal
Resumo  O  cancro  coloretal  (CCR)  é  uma  das  mais  importantes  causas  de  morte  ao  nível
mundial. O  cancro  coloretal  hereditário  está  associado  a  cerca  de  5  a  10%  de  todos  os  casosSíndromes
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de CCR.  Neste  artigo  faz-se  uma  revisão  da  abordagem  dos  principais  síndromas  hereditários
associados  a  CCR  de  acordo  com  a  literatura  mais  recente.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é
um artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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r. Introduction
olorectal  cancer  (CRC)  is  one  of  the  most  important  causes
f  death  in  the  world.  In  Portugal,  CRC  has  the  second  high-
st  incidence  after  breast  cancer  in  female  and  prostate∗ Corresponding author.
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C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4ancer  in  men1 and  the  second  cause  of  cancer-related
eath.
The  cause  of  CRC  is  multifactorial,  with  inheritance  and
nvironment  assuming  the  most  relevant  roles.  Approxi-
ately  70--80%  of  CRC  cases  seem  to  be  sporadic,  while  the
emaining  20--30%  is  associated  with  an  inherited  pattern.
atients  with  a  familial  risk  make  up  approximately  20%  of
ll  patients  with  colorectal  cancer,  whereas  approximately
--10%  of  the  total  annual  burden  of  colorectal  cancer  is
ereditary  and  Mendelian  in  nature.
 by Elsevier España, S.L.U. This is an open access article under the
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Table  1  Amsterdam  I  and  II  criteria  for  diagnosis  of  hered-
itary non-polyposis  colorectal  cancer.
Amsterdam  I  criteria
1.  Three  or  more  relatives  with  histologically  veriﬁed
colorectal  cancer,  1  of  which  is  a  ﬁrst-degree  relative  of
the other  two.  Familial  adenomatous  polyposis  should  be
excluded.
2. Two  or  more  generations  with  colorectal  cancer.
3. One  or  more  colorectal  cancer  cases  diagnosed  before
the age  of  50  years.
Amsterdam  II  criteria
1.  Three  or  more  relatives  with  histologically  veriﬁed
HNPCC-associated  cancer  (colorectal  cancer,  cancer  of
the endometrium,  small  bowel,  ureter,  or  renal  pelvis),  1
of which  is  a  ﬁrst-degree  relative  of  the  other  2.  Familial
adenomatous  polyposis  should  be  excluded.
2. Cancer  involving  at  least  2  generations.
3. One  or  more  cancer  cases  diagnosed  before  the  age  of  50
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Microsatellite  instability  testing  (sensibility  85%,  speciﬁcity
90%)  or  preferably  immunohistochemistry  testing  of  tumor
tissue  for  searching  the  lack  of  expression  of  MMR  gene
Table  2  Revised  Bethesda  guidelines.
1.  CRC  diagnosed  at  younger  age  than  50.
2. Presence  of  synchronous  or  metachronous  CRC  or  other
LS-associated  tumors.
3.  CRC  with  MSI-high  pathologic-associated  features
(Crohn-like  lymphocytic  reaction,  mucinous/signet  cell
differentiation,  or  medullary  growth  pattern)  diagnosed
in an  individual  younger  than  60  years  old.
4. Patient  with  CRC  and  CRC  or  LS-associated  tumor
diagnosed  in  at  least  1  ﬁrst-degree  relative  younger  than
50 years  old.
5.  Patient  with  CRC  and  CRC  or  LS-associated  tumor
(colorectum,  endometrium,  stomach,  ovary,  pancreas,Management  of  patients  with  hereditary  colorectal  cancer  s
Screening  for  hereditary  cancer  syndromes  in  patients
with  CRC  should  include  review  of  personal  and  family  his-
tories  and  genetic  evaluation  according  to  more  or  less
established  criteria.
A  diagnosis  of  Lynch  syndrome,  familial  adenomatous
polyposis,  or  another  genetic  syndrome  can  inﬂuence  clin-
ical  management  of  patients  with  CRC  and  their  family
members.  A  timely  identiﬁcation  of  individuals  at  risk  for
hereditary  CRC  syndromes  offers  an  opportunity  to  a  sooner
intervention  or  prevention.
In this  review  we  will  focus  on  the  major  forms  of
hereditary  colorectal  cancer,  Lynch  syndrome,  familial  ade-
nomatous  polyposis,  MUTYH  polyposis,  juvenile  polyposis,
Peutz--Jeghers  syndrome  and  serrated/hyperplastic  polypo-
sis  syndrome.
2. Lynch syndrome
Lynch  syndrome  (LS)  is  an  autosomal  dominant  condition
caused  by  a  defective  mismatch  repair  (MMR)  gene.
Although  this  syndrome  has  also  been  known  as  HNPCC
(hereditary  non-polyposis  colorectal  cancer),  this  terminol-
ogy  is  now  reserved  to  patients  and/or  families  who  fulﬁll
the  Amsterdam  criteria.  The  LS  denomination  must  be  only
applied  to  patients  and  families  in  which  the  genetic  basis
can  be  linked  to  a  germline  mutation  in  one  of  the  DNA  MMR
genes  or  the  EPCAM  gene.
Lynch-like  syndrome  patients  display  alterations  in  MMR
molecular  immunohistochemical  or  microsatellite  instability
(MSI)  without  an  identiﬁable  germline  mutation.  Famil-
iar  colorectal  cancer  type  X  refers  to  patients  that  meet
Amsterdam  I  criteria  without  LS  MSI  characteristics.
LS  is  responsible  for  approximately  3%  of  all  of  the
newly  diagnosed  colorectal  cancer  and  is  probably  the  most
common  hereditary  CRC.2 In  fact,  the  major  clinical  conse-
quence  of  LS  is  CRC  with  a  life-time  risk  varying  between  15%
and  70%  depending  on  sex  and  MMR  mutated  gene.  Mean  age
of  CRC  diagnosis  is  10--15  years  earlier  than  sporadic  cases.3
These  CRC  are  predominantly  right  colon  located  and
have  a  very  rapid  adenoma--carcinoma  progression,  with  fre-
quent  reports  of  CRCs  arising  within  three  years  of  a  clearing
colonoscopy.  However,  CRC  prognosis  in  LS  patients  is  better
when  compared  to  sporadic  matched  stage  CRC.4
The  presence  of  CRC,  endometrial,  ovary,  urinary  tract,
stomach,  small  bowel  or  brain  cancer,  especially  at  young
ages  and  with  cancer  family  history,  should  lead  to  inves-
tigate  a  probable  hereditary  cancer.  In  this  clinical  setting
the  genetic  counseling  has  a  major  role  and  can  include  per-
sonal  and  family  cancer  history,  risk  assessment,  education,
informed  consent  and  genetic  testing.
Multiple  clinical  criteria  have  been  developed  to  iden-
tify  at  risk  patients.  Obviously,  all  members  of  an  already
known  Lynch  family  should  be  tested.  In  individuals  without
previously  Lynch  diagnosis,  the  two  most  used  are  Amster-
dam  criteria  (sensitivity  22%  and  speciﬁcity  98%)  and  Revised
Bethesda  Guidelines  (sensitivity  82%  and  speciﬁcity  77%)
but  other  clinical  criteria,  like  endometrial  cancer  below
50  years,  and  computational  prediction  systems  have  been
applied  as  well5 (Tables  1  and  2).
Patients  meeting  Amsterdam  criteria  should  undergo
direct  germline  testing.  On  the  other  hand,  for  those  whoyears.
eet  Revised  Bethesda  criteria,  evaluation  by  immunohis-
ochemical  testing  for  the  MLH1/MSH2/MSH6/PMS2  proteins
nd/or  testing  for  microsatellite  instability  is  suggested.
Universal  testing  for  all  newly  diagnosed  CRC  (or  CRC
atients  under  70  years  old)  is  currently  a  hot  topic  under
iscussion  (Fig.  1).  In  this  setting,  tumor  immunohistochem-
stry  testing  seems  to  be  more  sensitive  and  cost-effective
or  identifying  LS  patients  and  achieves  the  aim  of  reduced
orbidity  and  mortality.  However,  implementation  of  this
creening  system  is  complicated  and  requires  effective  mul-
idisciplinary  approach.6--9
As  long  as  the  clinical  criteria  to  search  LS  are  fulﬁlled,
ifferent  options  can  be  adopted  for  detecting  MMR  defect.
Tumor  testing  can  be  done  on  archived  formalin-
xed  tissue  for  surgical  resection  or  biopsies  specimens.ureter,  renal  pelvis,  biliary  tract,  brain,  small  bowel,
sebaceous  glands,  and  kerotoacanthomas)  at  any  age  in  2
ﬁrst-degree  or  second-degree  relatives.
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mutation or MLH1
promoter
hypermethylation
Genetic
counseling and
germline testing
(according to IHC)
Colorectal
cancer surgical
specimen
IHC testing Loss of MLH1& PMS2
Loss of others
MMR proteins
# - MSI is an alternative to IHC
IHC – immunohistochemical testing
MSI – microsatellite instability testing
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tFigure  1  Un
roteins  (sensibility  83%,  speciﬁcity  90%)  can  be  done
ccording  to  local  resources  and  expertise.
The  lack  of  a  speciﬁc  MMR  repair  gene  in  IHC  (MLH1,
SH2,  MSH6,  PMS2)  can  indicate  germline  testing  to  that
peciﬁc  gene.  However,  in  case  of  loss  of  MLH1/PMS2  protein
xpression  in  the  tumor,  analysis  of  BRAF  V600E  mutation  or
nalysis  of  methylation  of  the  MLH1  promoter  should  be  car-
ied  out  ﬁrst  to  rule  out  a  sporadic  case.  If  loss  of  any  of  the
ther  proteins  (MSH2,  MSH6,  PMS2)  is  observed,  germline
enetic  testing  should  be  done  for  the  genes  correspond-
ng  to  the  absent  proteins  (MSH2,  MSH6,  EPCAM,  PMS2,  or
LH1).
When  tumor  tissue  is  not  available,  we  should  consider
irect  genetic  testing.  Full  germline  genetic  testing  for
ynch  syndrome  should  include  DNA  sequencing  and  large
earrangement  analysis.10
Germline  testing  for  deleterious  mutation  in  MLH1,  MSH2,
SH6,  PMS2  and  EPCAM  can  conﬁrm  LS  diagnosis,  to  establish
t  risk  status  of  family  members  and  allow  an  adequately
lanning  of  their  management.  Also,  the  prompt  diagnosis
f  these  patients  facilitates  their  surgical  approach.
In  a  LS  mutation  known  family,  mutation  absence  in  an
ndividual  is  considered  a  negative  test  and  its  presence  is  a
ositive  test  leading  to  a  surveillance  plan  implementation.
hen  mutation  is  not  known  in  LS  pedigree,  at  risk  indi-
iduals  should  be  managed  as  a  positive  test  and  undergo
eriodic  assessments  as  new  genetic  data  emerge.
LS  patients  are  at  increasing  risk  of  colorectal  and  extra-
olonic  cancers  at  young  age  but  there  are  several  clinical
ifferences  according  to  the  gene  mutated.
MLH1-mutation  carriers  tend  to  develop  CRC  at  younger
ges,  whereas  MSH2  carriers  seem  to  be  at  higher  risk  for
xtracolonic  cancers.  MSH6  mutations  female  carriers  have
n  increased  risk  for  endometrial  cancer  which  may  sur-
ass  the  lifetime  CRC  risk.  In  contrast,  the  risks  for  CRC
nd  endometrial  cancer  seem  to  be  lower  among  individuals
b
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lal  screening.
ith  mutations  in  PMS2  compared  with  other  MMR  gene
utations.
Current  guidelines  do  not  tailor  recommendations
ccording  to  each  genetic  defect  and  suggest  surveillance
eginning  at  20--25  years,  including  clinical  history,  physical
xamination  and  patient  and  family  education.
Potential  psychosocial  problems  related  to  genetic  test-
ng  and  surveillance  must  be  monitored  and  prompt  referral
o  a  clinical  psychologist  should  be  done  if  increased  psy-
hological  stress  is  detected.11
CRC  is  the  major  consequence  of  LS  syndrome  and
olonoscopy  screening  is  the  only  measure  associated  to  a
ecreasing  CRC  incidence  and  mortality.12,13 Almost  all  soci-
ties  and  multitask  forces  recommend  total  colonoscopy  for
t-risk  persons  or  LS  patients,  every  1--2  years  beginning  at
0--25  years  or  2--5  years  before  the  youngest  case  in  the
amily  if  CRC  diagnosis  before  25  years  old.13
In  patients  with  MSH6  and  PMS2,  surveillance  could  start
t  30  or  35  years  respectively,  given  the  later  age  of  CRC
iagnosis.  The  screening  program  should  continue  until  age
0--75  or  comorbidity.
The  second  most  important  cancer  in  Lynch  Syndrome
s  endometrial  cancer  with  a  cumulative  lifetime  risk  up
o  60%.  Several  modalities  of  screening  have  been  debated
ut  none  of  these  show  beneﬁts  in  survival.  Most  societies
nd  multitask  forces  suggest  annual  pelvic  examination  and
ndometrial  sampling  starting  at  age  30--35  years.14,15
As  the  endometrial  cancer,  ovarian  cancer  screening  does
ot  have  a  survival  impact.  However,  annual  transvaginal
ltrasound  starting  at  the  same  age  is  suggested.7
Urinary  tract  cancer  in  LS  patients  has  an  estimate  life-
ime  risk  up  to  20%.  There  is  no  evidence  of  screening
eneﬁts.  Urinary  cytology  is  one  of  the  most  widely  used
creening  approaches,  but  the  lack  of  sensitivity  and  the
any  false  positive  results  requiring  invasive  procedures
ed  to  an  abandon  of  this  attitude  in  clinical  practice.
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Urinalysis  is  accessible  and  non-expensive  and  may  be  annu-
ally  considered  in  LS  patients  at  age  30--35  years.7
The  gastric  cancer  in  LS  has  a  lifetime  risk  around  8%.
The  majority  of  these  cancers  are  intestinal  and  amenable
to  endoscopic  surveillance.  Esophagogastroduodenoscopy
(EGD)  with  gastric  biopsy  should  be  done  at  age  30--35
years  with  Helicobacter  pylori  treatment  if  applicable.  Sub-
sequent  endoscopic  surveillance  may  be  considered  every
2--3  years.11,16
No  current  evidence  exists  to  support  routine  screening  of
small  bowel  cancer  in  LS  patients.  The  majority  of  these  can-
cers  seem  to  be  located  in  the  duodenum  or  ileum  and  within
the  reach  of  EGD  and  colonoscopy  with  ileal  intubation  which
may  be  the  only  reasonable  approach.17
The  pancreatic  screening  is  still  being  debated  but  almost
no  society  recommends  this  practice.  It  may  only  be  consid-
ered  if  a  pancreatic  cancer  diagnosis  exists  in  a  ﬁrst  degree
relative.18
Total  colectomy  with  ileorectal  anastomosis  is  the
standard  treatment  in  LS  patients  with  colon  cancer  or  colo-
rectal  lesions  not  removable  by  endoscopic  therapy.  The  high
rate  of  metachronous  CRC  in  LS  patients  with  segmental
resection  supports  this  approach.  For  patients  not  amenable
for  colorectal  screening  this  surgical  option  may  be  con-
sidered.  After  colectomy,  ﬂexible  sigmoidoscopy  every  two
years  is  recommended  by  some  societies.16,19
Hysterectomy  and  bilateral  salpingo-oophorectomy  can
be  recommended.  All  pros  and  cons  of  prophylactic  gyneco-
logical  surgery  should  be  discussed  in  LS  women  who  have
ﬁnished  childbearing  or  at  the  age  of  40.  Patient  consid-
erations  in  this  decision  could  include  uterine  cancer  risk
depending  on  MMR  gene  mutation,  morbidity  of  surgery  and
the  risk  of  menopausal  symptoms.  If  CRC  surgery  is  sched-
uled,  the  option  of  prophylactic  surgery  at  the  same  time
should  be  considered.20,21
Some  studies  suggest  that  aspirin  can  reduce  incidence
of  colorectal  and  extracolonic  cancers.  This  approach  can
be  discussed  with  patients  bearing  in  mind  patient-speciﬁc
risks,  beneﬁts,  and  uncertainties  of  treatment,  but  no
strong  evidence  exists  to  support  this  practice  as  a  formal
recommendation.22--24
Also,  patients  could  be  advised  to  stay  within  the  normal
weight  range  and  avoid  smoking.11
3. Familial adenomatous polyposis
Familial  adenomatous  polyposis  (FAP)  is  an  autosomal  dom-
inantly  inherited  syndrome  that  arises  from  a  germline
mutation  on  APC  tumor  suppressor  gene  with  a  nearly  100%
penetrance.  The  most  important  clinical  features  are  the
presence  of  hundreds  to  thousands  adenomas  throughout  the
colorectum  at  an  early  age  and  a  lifetime  risk  for  colorectal
cancer  close  to  100%.  FAP  accounts  for  approximately  1%  of
all  cases  of  colorectal  cancer.25
Patients  with  FAP  can  also  developed  benign  extracolonic
manifestations  as  fundic  gastric  polyps,  desmoid  tumors,
cutaneous  lesions,  osteomas,  odontomas,  adrenal  adeno-
mas  and  pigmented  ocular  fundic  lesions.  The  second  most
important  cancer  is  duodenal  cancer  (4--12%)  but  hepato-
blastoma  (1--2%  at  age  ﬁve),  thyroid  (<2%),  pancreatic,  brain
and  biliary  tree  cancer  can  also  occur.
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Some  variants  of  FAP  are  known  by  speciﬁc  clinical  fea-
ures  like  Gardner  syndrome  (sebaceous  cysts,  osteomas,
ental  abnormalities),  Turcot  syndrome  (medulloblastomas)
nd  attenuated  FAP.  Attenuated  FAP  is  characterized  by  right
olon  predominance  oligopolyposis  and  typically  delayed
RC,  arising  from  a  mutation  at  the  extreme  3′ or  5′ end
f  the  APC  gene.
Despite  the  selective  disadvantage  of  the  disease,  the
ncidence  of  FAP  is  maintained  by  the  frequency  of  new
utation  which  may  reach  one  quarter  of  patients.  In  these
ases  the  clinical  suspicion  is  essential  for  diagnosis  and
enetic  testing.26
All  patients  with  a  FAP  ﬁrst-degree  relative  should  be  pro-
osed  to  APC  gene  testing  at  10--12  years,  as  well  as  all
ndividuals  presenting  classic  PAF  phenotype.
For  patients  with  10  or  more  cumulative  colorectal  ade-
omas  the  genetic  testing  should  also  be  done.  Genetic
ounseling  is  an  essential  part  of  genetic  testing.
The  screening  program  should  begin  at  10--12  years  old
n  a patient  with  a  mutation  positive  test  or  if  the  patient
s  a  ﬁrst  degree  relative  of  a  PAF  patient  without  a  known
utation,  which  account  to  nearly  20%  of  the  cases.
Annual  sigmoidoscopy  is  recommended  until  appearance
f  colorectal  adenomas.  After  that,  annual  colonoscopy
hould  be  performed  until  the  late  adolescence  or  appear-
nce  of  advanced  lesions  not  amenable  to  therapeutic
ndoscopy  that  lead  to  an  earlier  surgical  approach.
Several  programs  of  surveillance  have  been  proposed  for
atients  with  familiar  PAF  history  without  identiﬁed  muta-
ion  Most  of  these  suggest  annual  sigmoidoscopy  beginning
t  10--12  until  25  years  and  bi-annual  thereafter  until  30.
fter  that  age,  in  the  absence  of  colorectal  lesions,  the  sig-
oidoscopy  could  be  done  every  three  years  and  after  the
ge  of  50,  the  approach  could  be  done  as  an  average  risk
olorectal  cancer  patient.16,27
After  that  age,  in  the  absence  of  colorectal  lesions,  the
igmoidoscopy  could  be  done  every  three  years  and  after
he  age  of  50,  individuals  could  be  managed  as  average  risk
olorectal  patients.
Currently,  chemoprophylaxis  is  not  recommended  as  a
rimary  approach.28
Total  colectomy  is  the  only  deﬁnitive  approach  to  pre-
ent  CCR  in  FAP  patients.  Although  most  PAF  patients  were
roposed  to  a surgical  approach  between  16  and  25  years
ld,  this  timing  should  be  individualized  according  to  num-
er  and  histologic  features  of  polyps,  family  history  of  early
ancer  or  genetic  disposition.16
Prophylactic  surgical  options  are  either  colectomy  and
leorectal  anastomosis  (IRA)  or  proctocolectomy  and  ileal
ouch-anal  anastomosis  (IPAA).29,30
Both  surgical  techniques  have  pros  and  cons  namely  sur-
ical  complexity,  preservation  on  sphincter  function  and
ertility,  quality  of  life,  postsurgical  endoscopic  surveillance
imings  and  CCR  risk.
IRA  is  technically  straightforward  and  has  a low  compli-
ation  rate,  namely  sexual  or  bladder  dysfunction.  However,
atients  who  undergo  colectomy  with  IRA  are  at  a  25%  risk  of
eveloping  cancer  in  the  retained  rectum  after  20  years.31IPAA  is  preferable  in  extensive  rectal  polyposis,  curable
ectal  cancer  or  in  patients  not  reliable  for  remaining  rectum
urveillance.  Recent  studies  also  favor  IPAA  approach  in  view
o  reduce  CCR  risk.32,33
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Table  3  Spigelman  classiﬁcation.
Criteria  Grade  (points)
1  2  3
Polyps  number  1--4  5--20  >20
Size 1--4  5--10  >10
Histology  Tubular  Tubular-villous  Villous
Dysplasia  Low  Moderate  High
Stage 0 (0 points); Stage I (1--4 points); Stage II (5--6 points);
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recessive  inheritance  pattern.49 Biallelic  MUTYH  mutationsStage III (7--8 points); Stage IV (9--12 points).
Although  total  proctocolectomy  with  permanent  end
leostomy  removes  the  risk  of  CCR  cancer,  the  inevitable  and
eﬁnitive  stoma  limits  this  approach  to  patients  not  suitable
or  anastomotic  options  or  locally  advanced  CCR.
After  colectomy,  the  remaining  rectum,  ileal  pouch  or
erminal  ileum  has  to  be  addressed.
In  IRA  approach,  it  may  be  reasonable  to  begin  rectal
ndoscopic  surveillance  six  months  after  surgery  and  then
nce  a  year.  The  initial  surveillance  can  be  the  same  for  IPAA
r  terminal  ileostomy  but  further  endoscopic  evaluations
an  be  extended  to  every  2--3  years.  Polyps  found  should
e  endoscopically  removed,  if  possible,  prompt  reoperation
hould  be  planned  in  case  there  is  a  diagnosis  of  at  least  CCR
1.
Postsurgical  chemoprophylaxis  can  be  suggested  but,
owadays,  it  is  not  known  if  polyps’  reduction  decreases
ancer  risk.  Furthermore,  the  beneﬁts  of  these  agents
n  long-term  use  need  to  be  closely  weighed  against  the
isk  of  potential  gastrointestinal  and  cardiovascular  side
ffects.28,34,35
For  upper  gastrointestinal  cancer  most  societies  recom-
end  upper  endoscopy  every  two  years  from  the  age  of  25.
xial  endoscopic  view  allows  an  observation  of  gastric  and
uodenal  lesions  but  for  Vater  ampulla  deﬁnition,  it  may
e  more  adequate  with  lateral  endoscopic  view.  Chromoen-
oscopy  with  indigo  carmine  dye  may  be  considered.36
There  is  no  clear  evidence  to  support  screening  for  gastric
ancer  in  FAP  patients.  However,  given  the  increased  risk  for
uodenal  cancer,  the  stomach  should  be  examined  at  the
ame  time  of  duodenoscopy.
In  Spigelman  classiﬁcation,  four  stages  are  deﬁned
ccording  to  number,  size  and  histology  features  of  duode-
al  polyps,  which  allow  us  to  decide  future  follow-up  and
herapeutic  approach  (Table  3).37
The  next  upper  endoscopy  surveillance  is  recommended
n  5  years  for  stage  0--I;  3  years  for  stage  II,  1--2  years  for
tage  III  and  every  six  months  for  stage  IV.
In  stage  0-II  patients,  neither  chemoprophylaxis  nor
urgical  approach  are  indicated.  In  stage  II--III  only  chemo-
rophylaxis  is  suggested.  The  therapeutic  role  of  endoscopy
s  not  yet  established  in  these  patients  but  it  may  delay  a
tage  progression.  In  stage  IV  patients,  surgical  approach
Whipple  or  duodenectomy  if  possible)  is  consensual  but
ew  therapeutic  endoscopic  techniques  are  emerging  in  this
etting.38Enteroscopy  capsule  or  small  bowel  radiographic  contrast
tudy  started  at  the  age  of  20  or,  eventually,  preoperative
nteroscopy  at  the  colectomy  time  can  be  suggested  for
a
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mall  bowel  evaluation,  according  to  local  resources  and
xpertise,  but  more  studies  are  needed  in  this  setting.39--41
Adequate  physical  examination  for  searching  abdominal
asses,  namely  desmoids  tumors,  is  essential.  Abdominal
ltrasound,  CT  scan  or  RNM  may  be  helpful,  especially  in
atients  with  familial  history,  starting  1--2  years  after  colec-
omy  and  then  every  5--10  years.
If  intra-abdominal  or  abdominal  wall  desmoids  are
etected,  medical  therapeutic  with  sulindac  and  tamoxifen
an  be  suggested.  Surgery,  chemotherapy  (doxorubicine  and
acarbazine  or  methotrexate  and  vinblastine)  or  radiation
herapy  are  also  available  options.42
Thyroid  physical  evaluation  and  complementary  US
hould  begin  during  adolescence.43
For  children  with  affected  parents,  hepatoblastoma
hould  be  screened  until  5--7  years  old.  For  pancreatic
esions  no  additional  tests  are  recommended.27
For  attenuated  PAF,  surveillance  options  are  different
ccording  to  speciﬁc  clinical  features.  Total  colonoscopy
hould  be  the  initial  endoscopic  option  starting  at  late
eenage  years  and  then  every  2--3  years  until  adult  age.
hereafter,  yearly  total  colonoscopy  should  be  done  until
mportant  polyposis  occurs  and  colectomy  proposed.16 If  no
utation  is  found  surveillance  should  be  maintained  until  75
ears  old  or  comorbidities.16
If  Gardner  syndrome  is  detected,  the  speciﬁc  surveillance
s  limited  to  the  early  detection  of  osteomas  and  dental
bnormalities.  In  Turcot  syndrome,  regular  brain  tomogra-
hy  for  meduloblastoma  detection  may  be  considered.
For  these  three  speciﬁcs  phenotypes  the  remaining
urveillance  is  similar  to  classic  PAF.
. MUTYH associated polyposis
UTYH  associated  polyposis  (MAP)  is  the  only  autosomal
ecessive  polyposis  syndrome,  caused  by  biallelic  mutations
n  the  MUTYH  gene.44 Because  the  diagnostic  criteria  for  MAP
re  yet  to  be  established,  it  is  difﬁcult  to  diagnose  the  dis-
ase.  Furthermore,  the  clinical  features  of  MAP  may  vary.
lthough  with  a  clinical  presentation  similar  to  attenuated
AP,  it  is  now  clear  that  the  clinical  spectrum  of  MUTYH
ermline  mutations  is  broad  and  can  include  CRC  without
olyposis  or  even  overlapping  classic  FAP.45 In  this  syndrome,
denomatous  polyps  are  the  most  common  CRC  but  serrated
olyps  are  also  common.46
Although  the  increased  CRC  risk  in  patients  with  bial-
elic  mutations  is  well  established,  there  is  some  controversy
egarding  individuals  with  monoallelic  mutations.47
Extracolonic  disease  may  include  gastric  and  duodenal
olyps,  duodenal  carcinoma,  osteomas  and  dental  cyst,
reast  cancer  in  women,  congenital  hypertrophy  of  the
etinal  pigment  epithelium  and  sebaceous  gland  tumors
Muir-Torre  phenotype).  There  also  appears  to  be  an
ncreased  risk  of  ovarian  and  skin  cancer.48
MUTYH  screening  should  be  directed  to  patients  with
ore  than  10  adenomas  and/or  hyperplastic/serrated
olyps,  especially  in  the  context  of  a  family  history  withre  found  in  about  28%  of  APC  mutation-negative  patients
ith  10--100  polyps  and  in  14%  of  patients  with  more
han  100  polyps.50 Patients  without  Lynch  syndrome  and  a
yndromes  209
Table  4  Cumulative  risks  for  neoplasias  in  PJS.
Colorectal  39%
Breast  32--54%
Stomach  29%
Ovary  21%
Small  bowel  13%
Pancreas  11--36%
Cervix  10%
Testis  (Sertoli  cell) 9%
Table  5  Clinical  diagnostic  criteria  for  PJS.
Suggestive  family  history  of
Peutz--Jeghers  syndrome
AND.  .  .
Any  number  of  PJ  polyps
OR
Characteristic
mucocutaneous
pigmentation
Non-suggestive  family  history
AND. .  .
Two  or  more
histologically  conﬁrmed
PJ  polyps
OR
Any  number  of  PJ  polyps
in the  presence  of
characteristic
mucocutaneous
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cumulative  number  of  adenomas  between  ﬁve  and  nine
should  also  undergo  screening  for  MUTYH,  in  the  presence  of
an  appropriate  setting:  less  than  40  years  old,  at  least  ﬁve
advanced  adenomas,  association  with  sebaceous  neoplasms
or  duodenal  polyposis.51
Until  this  day,  there  are  no  widely  accepted  screening
guidelines  for  these  patients.  Biallelic  MUTYH  mutation  pos-
itive  patients,  or  a  not  tested  sibling  of  a  patient  with  MAP,
should  start  colonoscopy  at  the  age  of  25--30  and  repeat
every  2--3  years  if  normal.  If  polyps  are  found,  the  next
colonoscopy  should  be  in  1--2  years.16
However,  an  earlier  colonic  surveillance,  at  age  20  years,
is  also  suggested  by  some  societies  and  expert  panels.49,52
Although  colectomy  may  be  considered  at  the  age  of  21
years,  surgery  timing  should  be  individualized  according  to
polyposis  features  and  therapeutic  endoscopic  possibility.
The  surgical  approach  must  take  into  account  rectal  polyp
burden.
Upper  gastrointestinal  endoscopy  (including  duo-
denoscopy)  should  be  considered  every  3--5  years,  beginning
at  least  at  age  30--35  years.16,52
Women  with  biallelic  MUTYH  gene  mutations  may  be
consider  to  have  a  high-risk  breast  cancer  and  should  be
advised  for  adequate  surveillance.  At  least  one  dermatolog-
ical  observation  at  the  diagnosis  must  be  performed,  and
patients  should  be  aware  to  identify  new  skin  lesions.51
CRC  risk  associated  with  monoallelic  MUTYH  carriers  is
still  under  debate.  To  date  CRC  screening,  as  recommended
for  ﬁrst-degree  relatives  of  a  patient  with  sporadic  CRC,  is
advised.52
5. Peutz--Jeghers syndrome
Peutz--Jeghers  syndrome  (PJS)  is  a  rare  autosomal  dom-
inant  disorder  that  is  characterized  by  multiple  gas-
trointestinal  hamartomatous  polyps  and  lips  and  buccal
mucosa  pigmentation.53 Prevalence  is  estimated  to  be
1:100,000--1:200,00054 and  the  diagnosis  is  often  made  dur-
ing  the  second  decade,  with  a  median  age  of  11  years  old.55
The  most  common  and  known  cause  is  a  combination  of  a
ﬁrst  allele  germline  mutation  of  tumor  supressor  gene  STK11
with  a  somatic  one  of  the  second  allele.56
The  two  main  aspects  in  the  management  of  PJS  patients
are  the  long  term  cancer  risk  and  PJ  polyps  related
complications,  such  as  intussusception  and  bleeding.57 Indi-
viduals  have  an  increased  risk  for  gastrointestinal  and
non-gastrointestinal  neoplasms.  Lifetime  cumulative  risk  for
all  cancers  is  up  to  90%;  most  of  them  are  colorectal,  breast,
gastric  and  pancreatic  cancers,  but  other  tumors  have  been
associated  with  PJS  (Table  4).16,58,59
Clinical  diagnostic  criteria  have  been  established  in  2010
by  World  Health  Organization  and  revised  by  an  European
expert  consensus  (Table  5).60
Individuals  who  meet  clinical  criteria  for  PJS  should
undergo  genetic  testing  for  a  germline  mutation  in  the  STK11
gene  to  conﬁrm  diagnosis  and  counsel  family  members.  If  no
pathogenic  STK11  mutation  is  found  but  the  individual  meets
clinical  criteria  for  PJS,  the  clinical  criteria  prevail  over
genetic  test,  since  the  diagnosis  is  not  excluded  because  not
all  mutations  responsible  for  PJS  are  identiﬁed.61 In  families
with  an  unknown  mutation  it  is  necessary  to  search  those
t
h
tpigmentation.
ho  develop  early  SPJ  clinical  signs  and  then  offer  them
ppropriate  surveillance.61
None  of  the  screening  recommendations  have  been
alidated,  but  some  groups  of  experts  have  proposed  surveil-
ance  recommendations.
Endoscopic  surveillance  may  include62 a ﬁrst  upper  and
ower  gastrointestinal  endoscopy  at  eight  years  old.  If  polyps
re  present,  the  surveillance  should  be  repeated  every  three
ears;  if  not,  the  second  endoscopic  examination  can  be
one  at  age  18  and  then  every  three  years.  After  the  age
f  50  years,  colonoscopy  should  be  done  not  three  but  every
ne  to  two  years.  Also  at  age  eight  years,  video  capsule
ndoscopy  should  be  considered,  and  the  same  intervals  as
or  upper  and  lower  gastrointestinal  endoscopies  apply.
All  patients  with  Peutz--Jeghers  syndrome  should  be
creened  for  pancreatic  cancer,  regardless  the  family  his-
ory.  Suggestions  for  Initial  approach  include  endoscopic
ltrasonography  and/or  magnetic  resonance  cholangiopan-
reatography  which  can  begin  at  age  25  years  and  then  every
ne  to  two  years.17,60
Annual  breast  MRIs  are  recommended,  starting  by  the  age
f  25  years  and  regular  clinical  breast  examination  should
lso  be  performed.16
For  men,  annual  testicular  examination  starting  at  age  of
0  years  is  recommended.16
There  is  controversy  regarding  the  gynecological  can-
ers  screening  but  we  can  consider  CA-125  blood  test  and
ransvaginal  ultrasound.16,60,62No  speciﬁc  recommendation  for  lung  cancer  screening
as  been  made.  However,  education  about  smoking  cessa-
ion  should  be  performed.16
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. Juvenile polyposis syndrome
uvenile  polyposis  syndrome  (JPS)  is  a  rare  (<1:100,000)
utosomal  dominant  disease  with  high  penetrance,  char-
cterized  by  the  occurrence  of  juvenile  polyps  in  the
astrointestinal  tract  and  an  increased  risk  of  colorectal
ancer.63 JPS  is  associated  with  germline  mutations  in  three
enes  (SMAD4,  BMPR1A  and  ENG),  all  related  to  the  TGF-b
athway.  In  patients  fulﬁlling  the  diagnostic  criteria,  it  is
ossible  to  detect  mutations  in  only  approximately  50%.64
Juvenile  polyposis  syndrome  is  deﬁned  by  the  presence
f  ﬁve  or  more  juvenile  polyps  in  the  colon,  multiple  juve-
ile  polyps  found  throughout  the  gastrointestinal  tract  or
ny  number  of  juvenile  polyps  in  an  individual  with  a  posi-
ive  family  history  of  juvenile  polyposis.16 A  family  history
f  juvenile  polyps  is  found  in  20--50%,65 and  those  are  called
amilial  juvenile  polyposis.
The  disease  has  been  phenotypically  classiﬁed  into  three
ubsets,  but  these  forms  appear  to  be  variable  expres-
ions  of  the  same  disease.63 The  age  at  diagnosis  varies,
ut  symptoms  are  usually  present  in  the  ﬁrst  and  sec-
nd  decades  of  life.65 Typical  presenting  symptoms  include
ectal  bleeding,  anemia,  abdominal  pain,  diarrhea,  and
echanical  complications  such  as  intussusception,  obstruc-
ion,  and  polyp  prolapse.65
An  increased  cumulative  risk  for  both  colorectal  cancer
38%)  and  upper  GI  cancer  (21%)  has  been  documented.64
ancreatic  cancer  and  small  bowel  cancer  have  also  been
eported.63
Prophylactic  total  or  subtotal  colectomy  or  gastrectomy
hould  be  considered  in  patients  with  multiple  polyps,
evere  symptoms  or  a  family  history  of  CRC.64 Proctocolec-
omy  and  subtotal  colectomy  with  ileorectal  anastomosis
eed  endoscopic  follow-up  because  of  the  high  recurrence-
ate  of  polyps.
There  is  limited  data  and  therefore  no  wide  consensus  has
een  established  for  screening  or  for  the  surveillance  and
anagement  of  patients  with  clinical  diagnostic  features  of
uvenile  polyposis.
For  asymptomatic  at-risk  members  of  JPS  families  British
ecommendations  state  surveillance  with  colonoscopy  every
ne  to  two  years  starting  at  age  15--18  years  until  age
0  and  gastroduodenoscopy  starting  at  age  25  and  one  to
wo  year  interval  thereafter.66 Small-bowel  disease  is  not  a
igniﬁcant  clinical  problem  in  JPS  and  surveillance  should
ot  be  performed.67 There  are  no  suggestions  of  pancreatic
creening  modalities.
. Serrated polyposis syndrome
errated  polyposis  syndrome  (SPS)  is  a  rare  condition  char-
cterized  by  a  predisposition  to  serrated  polyps  and  an
ncreased  risk  for  colorectal  cancer  and  possibly  some  other
xtracolonic  neoplasms.
In  contrast  to  FAP  and  Lynch  syndrome,  no  genetic
bnormality  has  been  consistently  described  in  SPS,  but
nheritance  is  seen  in  a  small  percentage  of  families.68Although  routine  germline  testing  is  not  routinely  recom-
ended  for  SPS  patients,  MUTYH  testing  may  be  considered
f  concurrent  adenomas  and/or  a  family  history  of  adenomas
re  present.69C.  Brandão,  J.  Lage
SPS  is  generally  described  as  the  presence  of  multi-
le,  large  and/or  proximal  hyperplastic/serrated  polyps.70
errated  polyps,  as  characterized  by  the  saw-toothed
rchitecture,  comprise  heterogeneous  lesions,  including
yperplastic  polyps,  sessile  serrated  adenomas,  traditional
errated  adenomas  and  mixed  lesions  of  these.71--73
Clinical  criteria  for  diagnosis  were  deﬁned  by  the  World
ealth  Organization  and  include  at  least  one  of  the  fol-
owing:  at  least  ﬁve  serrated  polyps  proximal  to  sigmoid
olon  with  ≥2  of  these  being  >20  mm,  any  number  of  ser-
ated  polyps  proximal  to  the  sigmoid  colon  in  an  individual
ho  was  a ﬁrst-degree  relative  with  serrated  polyposis  and
20  serrated  polyps  of  any  size  distributed  throughout  the
olon.74
There  are  no  available  studies  regarding  the  effective-
ess  of  surveillance  in  SPS.  However,  based  on  cancer  risk,
hese  patients  should  undergo  colonoscopies  every  1--3  years
ith  attempted  removal  of  all  polyps  or,  at  least,  all  polyps
igger  than  5  mm.16,75
The  inability  to  control  polyps  growth  constitutes  an  indi-
ation  to  colectomy  with  IRA.
Screening  recommendations  for  individuals  from  SPS  fam-
lies  are  not  yet  established  but  it  is  reasonable  to  screen
rst  degree  relatives  based  on  results  of  baseline  evaluations
n  family  members.9
. Conclusion
n  summary,  it  is  important  to  be  aware  of  the  possibility  of
RC  associated  hereditary  syndromes.  A  timely  identiﬁca-
ion  of  these  syndromes  is  a  unique  opportunity  to  a  sooner
nd  efﬁcient  CRC  prevention  and  management.
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